drugset / Trial / NCT00520325
A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the dose of EZN-2232 that can be given to MBL deficient pediatric cancer patients undergoing chemotherapy. The pharmacokinetics, pharmacodynamics, and safety of the study drug will also be studied.
Timeline
- Start
- 2007-06
- Primary completion
- 2009-06
- Completion
- 2009-08
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision to terminate the study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rhMBL | Protein / enzyme biologic | 0.5 mg/kg | Intravenous |
| Subject | rhMBL | Protein / enzyme biologic | 1 mg/kg | Intravenous |